News

Several talks expected to focus on the latest treatment updates, as well as some recently published data on COVID-19 symptoms and a commonly-used atopic dermatitis treatment.

Energy and autos lead the way, health care relatively stable

Vial launches Vial Dermatology contract research organization (CRO) and highlights how it could improve the speed and quality of clinical trials.

A national survey found that patients are willing to try medical cannabis products as potential treatments of their condition. Additionally, some already use over-the-counter cannabis products.

The new year promises to be rich with dermatology game changers following a sluggish 2021 for breakthroughs and FDA approvals.

Click to see a preview of what to expect this week.

ICYMI, this week we had stories on the continued issues with iPLEDGE, the new data on spesolimab treatment for GPP, and more.

The Skin of Color Society released an article detailing its 2021 achievements, containing what the society considers its most active and successful year.

But mask-wearing still vital to slowing spread of disease, agency says.

Click to see a preview of what to expect this week.

ICYMI, some of this week’s featured content includes an exclusive interview about lasers and acne, and articles on 2021's top 20 stories, the declining preference for telehealth, and more.

Dermatology Times® broke the news that the carcinogen benzene was found in multiple sunscreens, but that wasn’t the only major headline of the year. We revisit the 20 stories of 2021 that made the greatest impact.

Two possible explanations for declining contentment with live video calls as a form of care delivery.

A recent study investigates the probability of BDD in cosmetic dermatology with the help of a new screening tool.

This week's edition of the Mainstream Patients features stories about the best hair removal methods, pH levels in the skin, and more.

Click to see a preview of what to expect this week.

Don't Forget to take this week's poll.

ICYMI, some of this week’s featured content includes an exclusive interview about the occupational dermatoses, and articles on 2021's breakthroughs and disappointments, the risk of psoriasis related to BMI and more.

Click to see a preview of what to expect this week.

Click here to answer this week's poll.

ICYMI, some of this week’s featured content includes an exclusive interview about the iPLEDGE program issues, and articles on FDA approval of upadacitinib for psoriatic arthritis, ruxolitinib cream receiving Priority Review from the FDA for vitiligo, and more.

John Barbieri, MD, MBA, FAAD, speaking in his capacity as a member of the AADA iPLEDGE Workgroup, talks with Dermatology Times® about the recent iPLEDGE website struggles and guidance on how dermatologists should handle the situation.

Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, sits down with Dermatology Times® to discuss what changes were made to the iPLEDGE platform, examples of how the roll out has been unsuccessful, and how patients should be wary of trying to take old medications.

In this video interview, Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, explains what happened with the iPLEDGE website.

Physicians and their teams have been unable to access the iPLEDGE site during an update to incorporate an FDA-approved modification to the iPLEDGE REMS that took effect December 13, 2021.

Arcutis Biotherapeutics has announced data suggesting that the vehicle in the investigational roflumilast cream had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema.

Click to see a preview of what to expect this week.

ICYMI, some of this week’s featured content includes an exclusive interview about the unmet needs of vitiligo patients, and articles on international impetigo guidelines, the newly released tapinarof data, and more.

A new study in the Journal of General Internal Medicine finds compliance remains lacking a year after federal price transparency rules went into effect.

Telehealth visits increased, but overall utilization of Part B declined